Evidence map›Paper›PMID 35230188›Full record

ArticleRadiology2022

Radiomics-based Cluster Groups to Predict Clinical-Pathologic and Genomic Characteristics of Stage I Lung Adenocarcinoma.

Mizuki Nishino

Abstract readEditorialComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mizuki NishinoFrom the Department of Radiology, Brigham and Women's Hospital, Boston, Mass; and Department of Imaging, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215.ORCID 0000-0003-0275-0502

Funding

The Boston Lung Cancer Survival CohortU01CA209414 · NCI · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI David C Christiani · 2017 to 2026
$12.2M
Interstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4M
Automated in vivo analysis of tumor growth rate as a guide for therapeutic decisions to advance personalized cancer treatmentR01CA203636 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI NISHINO, MIZUKI · 2017 to 2021
$2.9M
Early change in plasma tumor DNA as a patient and trial-level diagnostic in advanced lung cancerR01CA240592 · NCI · DANA-FARBER CANCER INST · PI PAWELETZ, CLOUD PETER · 2020 to 2024
$2.2M
NCI NIH HHS R01 CA203636NCI NIH HHS R01 CA240592NCI NIH HHS U01 CA209414NHLBI NIH HHS R01 HL111024
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Adenocarcinoma of LungLung NeoplasmsGenomicsHumansTomography, X-Ray Computed

Identifiers

PMID35230188
PMCPMC9131164

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.